Changseok Kim1,2, Raelene M Wouda3, Juan Borrego4, Esther Chon1,5. 1. Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA. 2. Denney Veterinary Services, Vicksburg, MI, USA. 3. Department of Clinical Sciences, Kansas State University, College of Veterinary Medicine, Manhattan, KS, USA. 4. Hospital Aúna Especialidades Veterinarias, Valencia, Spain. 5. MedVet Indianapolis, Carmel, IN, USA.
Abstract
OBJECTIVES: The aims of this study were to evaluate the response, outcome and prognostic factors in cats with clinically presumed relapsed low-grade alimentary lymphoma (LGAL) receiving cyclophosphamide as a first-line rescue therapy after failing chlorambucil treatment. METHODS: The medical records of 20 cats (from three institutions, between 2002 and 2017) treated with cyclophosphamide for relapsed LGAL after initial treatment with chlorambucil were retrospectively reviewed. Progression-free survival (PFS), overall survival time (OST) and the association of select variables with measures of outcome were assessed. Adverse events (AEs) were also described. RESULTS: Eighteen cats (90%) achieved a complete clinical response (CR) for a median duration of 239 days. The median PFS was 215 days. The median OST was 1065 days. The only clinical factor associated with a longer PFS was achievement of a CR with cyclophosphamide treatment. Cyclophosphamide was associated with few and reversible constitutional, gastrointestinal and hematologic AEs. CONCLUSIONS AND RELEVANCE: Cyclophosphamide appears to be a safe and effective first-rescue therapeutic option for cats with relapsed LGAL.
OBJECTIVES: The aims of this study were to evaluate the response, outcome and prognostic factors in cats with clinically presumed relapsed low-grade alimentary lymphoma (LGAL) receiving cyclophosphamide as a first-line rescue therapy after failing chlorambucil treatment. METHODS: The medical records of 20 cats (from three institutions, between 2002 and 2017) treated with cyclophosphamide for relapsed LGAL after initial treatment with chlorambucil were retrospectively reviewed. Progression-free survival (PFS), overall survival time (OST) and the association of select variables with measures of outcome were assessed. Adverse events (AEs) were also described. RESULTS: Eighteen cats (90%) achieved a complete clinical response (CR) for a median duration of 239 days. The median PFS was 215 days. The median OST was 1065 days. The only clinical factor associated with a longer PFS was achievement of a CR with cyclophosphamide treatment. Cyclophosphamide was associated with few and reversible constitutional, gastrointestinal and hematologic AEs. CONCLUSIONS AND RELEVANCE: Cyclophosphamide appears to be a safe and effective first-rescue therapeutic option for cats with relapsed LGAL.
Authors: Peter S Czajkowski; Nicola M Parry; Carrie A Wood; Sue A Casale; Whitney E Phipps; Jennifer A Mahoney; Daniel I Spector; Lori Lyn Price; John Berg Journal: Front Vet Sci Date: 2022-06-27